Bilateral Renal Oncocytoma: Active Surveillance Versus Partial Nephrectomy.

active surveillance bilateral renal oncocytoma birt-hogg-dube syndrome core renal biopsy partial nephrectomy renal cell carcinoma

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Feb 2022
Historique:
accepted: 16 02 2022
entrez: 30 3 2022
pubmed: 31 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

Renal oncocytomas (ROs) are benign tumors comprising 16% of renal masses. Due to the overlapping phenotypes seen in RO and chromophobe renal cell carcinoma (RCC) and lack of specific clinical and laboratory characteristics of RO, physicians face a challenge when arriving at a definitive diagnosis of RO. ROs additionally appear indistinct from RCCs on CT scan, contributing further to the difficulty of arriving at a clear diagnosis of RO.  This is a case report of a 66-year-old man who presented with flank pain found to be related to bilateral ROs and underwent bilateral partial nephrectomies. ROs are benign small renal masses that often pose a diagnostic challenge since preoperative diagnosis can be difficult to achieve. Given advancements in technology, active surveillance with core renal biopsy is a promising approach to accurately diagnose and manage ROs conservatively. The application of these techniques has wide-reaching implications for patients and physicians by reducing the need for a potentially harmful surgery and creating a cost-effective way to manage a diagnosis.

Identifiants

pubmed: 35350482
doi: 10.7759/cureus.22303
pmc: PMC8933140
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e22303

Informations de copyright

Copyright © 2022, Sathe et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
Urol Oncol. 2013 Jan;31(1):57-62
pubmed: 21719322
Korean J Radiol. 2015 Jan-Feb;16(1):99-113
pubmed: 25598678
BJU Int. 2011 Sep;108(6):816-9
pubmed: 21166765
Eur J Intern Med. 2008 Nov;19(7):e67-9
pubmed: 19013370
J Urol. 1999 Jul;162(1):40-2
pubmed: 10379735
J Urol. 2011 Mar;185(3):795-801
pubmed: 21239013
Scand J Urol Nephrol. 2001 Apr;35(2):150-2
pubmed: 11411660
Nephrol Dial Transplant. 1997 May;12(5):1034-6
pubmed: 9175065
J Clin Pathol. 2007 Jun;60(6):720-2
pubmed: 17557872
Can J Urol. 2010 Apr;17(2):5131-4
pubmed: 20398456
J Urol. 2009 Jul;182(1):41-5
pubmed: 19450840
Oncol Lett. 2016 Jul;12(1):291-294
pubmed: 27347140
J Urol. 1993 Aug;150(2 Pt 1):295-302
pubmed: 8326547
Urology. 2002 May;59(5):635-42
pubmed: 11992832
Urologia. 2021 May;88(2):122-124
pubmed: 33292059
BMC Urol. 2017 Jan 12;17(1):6
pubmed: 28081704
Urol Oncol. 2012 Jul-Aug;30(4):362-8
pubmed: 20171908
J Urol. 2016 Mar;195(3):581-6
pubmed: 26388501

Auteurs

Abha Sathe (A)

Urology, California Northstate University College of Medicine, Elk Grove, USA.

David Lindars (D)

Urology, California Northstate University College of Medicine, Elk Grove, USA.

Pranav Sathe (P)

Urology, California Northstate University College of Medicine, Elk Grove, USA.

Rithvik Nallapareddy (R)

Urology, California Northstate University College of Medicine, Elk Grove, USA.

Tim Grennan (T)

Hematology and Medical Oncology, California Northstate University College of Medicine, Elk Grove, USA.

Classifications MeSH